PL2178921T3 - Monoklonalne przeciwciała przeciwko glipikanowi-3 - Google Patents
Monoklonalne przeciwciała przeciwko glipikanowi-3Info
- Publication number
- PL2178921T3 PL2178921T3 PL08796249T PL08796249T PL2178921T3 PL 2178921 T3 PL2178921 T3 PL 2178921T3 PL 08796249 T PL08796249 T PL 08796249T PL 08796249 T PL08796249 T PL 08796249T PL 2178921 T3 PL2178921 T3 PL 2178921T3
- Authority
- PL
- Poland
- Prior art keywords
- monoclonal antibodies
- antibodies against
- against glypican
- glypican
- monoclonal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95984507P | 2007-07-17 | 2007-07-17 | |
| EP08796249.4A EP2178921B1 (en) | 2007-07-17 | 2008-07-17 | Monoclonal antibodies against glypican-3 |
| PCT/US2008/070344 WO2009012394A1 (en) | 2007-07-17 | 2008-07-17 | Monoclonal antibodies against glypican-3 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2178921T3 true PL2178921T3 (pl) | 2016-06-30 |
Family
ID=39874207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL08796249T PL2178921T3 (pl) | 2007-07-17 | 2008-07-17 | Monoklonalne przeciwciała przeciwko glipikanowi-3 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US8680247B2 (https=) |
| EP (1) | EP2178921B1 (https=) |
| JP (2) | JP5868593B2 (https=) |
| KR (2) | KR101570252B1 (https=) |
| CN (1) | CN101815726B (https=) |
| AU (1) | AU2008275985B2 (https=) |
| CY (1) | CY1117236T1 (https=) |
| DK (1) | DK2178921T3 (https=) |
| ES (1) | ES2562790T3 (https=) |
| HR (1) | HRP20160270T1 (https=) |
| HU (1) | HUE028737T2 (https=) |
| ME (1) | ME02345B (https=) |
| MX (1) | MX2010000537A (https=) |
| PL (1) | PL2178921T3 (https=) |
| PT (1) | PT2178921E (https=) |
| RS (1) | RS54624B1 (https=) |
| SI (1) | SI2178921T1 (https=) |
| WO (1) | WO2009012394A1 (https=) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| ES2892925T3 (es) | 2006-03-31 | 2022-02-07 | Chugai Pharmaceutical Co Ltd | Métodos para controlar la farmacocinética en sangre de anticuerpos |
| KR101570252B1 (ko) * | 2007-07-17 | 2015-11-19 | 메다렉스, 엘.엘.시. | 글리피칸-3에 대한 단클론 항체 |
| CN101874042B9 (zh) | 2007-09-26 | 2019-01-01 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| KR20150126724A (ko) * | 2007-09-28 | 2015-11-12 | 추가이 세이야쿠 가부시키가이샤 | 혈장 중 반응속도가 개선된 항-글리피칸-3 항체 |
| CL2009000647A1 (es) * | 2008-04-04 | 2010-06-04 | Chugai Pharmaceutical Co Ltd | Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto. |
| US8404811B2 (en) | 2009-05-08 | 2013-03-26 | Genentech, Inc. | Humanized anti-EGFL7 antibodies and methods using same |
| US9260492B2 (en) | 2010-11-15 | 2016-02-16 | Pieris Ag | Muteins of human lipocalin 2 with affinity for glypican-3 (GPC-3) |
| RS67768B1 (sr) | 2010-11-30 | 2026-03-31 | Chugai Pharmaceutical Co Ltd | Terapijski agens koji indukuje citotoksičnost |
| JP6001456B2 (ja) * | 2010-12-28 | 2016-10-05 | 中外製薬株式会社 | 動物細胞の培養方法 |
| CN105968209B (zh) | 2011-04-19 | 2021-08-03 | 美国政府(由卫生和人类服务部的部长所代表) | 对磷脂酰肌醇蛋白聚糖3特异的人单克隆抗体及其用途 |
| US8852599B2 (en) | 2011-05-26 | 2014-10-07 | Bristol-Myers Squibb Company | Immunoconjugates, compositions for making them, and methods of making and use |
| WO2013070468A1 (en) * | 2011-11-08 | 2013-05-16 | The Trustees Of The University Of Pennsylvania | Glypican-3-specific antibody and uses thereof |
| SG11201407972RA (en) * | 2012-06-01 | 2015-01-29 | Us Health | High-affinity monoclonal antibodies to glypican-3 and use thereof |
| CN103833852A (zh) * | 2012-11-23 | 2014-06-04 | 上海市肿瘤研究所 | 针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体 |
| RS56169B1 (sr) | 2013-02-14 | 2017-11-30 | Bristol Myers Squibb Co | Jedinjenja tubulisina, metode pripreme i primena |
| KR20160068738A (ko) | 2013-08-14 | 2016-06-15 | 윌리엄 마쉬 라이스 유니버시티 | 운시알라마이신의 유도체, 합성 방법 및 항종양 제제로서 이들의 용도 |
| JP6534615B2 (ja) | 2013-09-27 | 2019-06-26 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
| US10093746B2 (en) | 2014-09-04 | 2018-10-09 | The Trustees Of The University Of Pennsylvania | Glypican-3 antibody and uses thereof |
| MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| US10077287B2 (en) | 2014-11-10 | 2018-09-18 | Bristol-Myers Squibb Company | Tubulysin analogs and methods of making and use |
| JP6668345B2 (ja) | 2014-11-21 | 2020-03-18 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 修飾された重鎖定常領域を含む抗体 |
| CN104829704B (zh) * | 2014-12-15 | 2016-08-17 | 河北省科学院生物研究所 | 一种磷脂酰肌醇蛋白聚糖gpc3蛋白片段及其应用和制备的杂交瘤细胞株 |
| JP6676058B2 (ja) | 2015-01-14 | 2020-04-08 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ヘテロアリーレン架橋したベンゾジアゼピン二量体、そのコンジュゲート、ならびに製造および使用方法 |
| TW201632531A (zh) | 2015-01-14 | 2016-09-16 | 必治妥美雅史谷比公司 | 苯二氮呯二聚物，其結合物及製造與使用方法 |
| JP7082484B2 (ja) | 2015-04-01 | 2022-06-08 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
| CN105037540A (zh) * | 2015-05-13 | 2015-11-11 | 北京比洋生物技术有限公司 | 抗磷脂酰肌醇蛋白聚糖3全人源抗体 |
| MX390894B (es) | 2015-05-18 | 2025-03-21 | Pieris Pharmaceuticals Gmbh | Polipéptido de fusión anti-cáncer. |
| AU2016262838B2 (en) | 2015-05-18 | 2020-10-08 | Pieris Pharmaceuticals Gmbh | Muteins of human lipocalin 2 with affinity for Glypican-3 (GPC3) |
| CN113881694A (zh) * | 2015-06-24 | 2022-01-04 | 学校法人庆应义塾 | 抗磷脂酰肌醇蛋白聚糖-1-免疫抗原受体 |
| US12168061B2 (en) * | 2015-08-03 | 2024-12-17 | Crage Medical Co., Limited | Antibody against glypican-3 and application thereof |
| KR101796688B1 (ko) | 2015-10-29 | 2017-12-01 | 재단법인 목암생명과학연구소 | 신규 항-글리피칸 3 항체 및 이를 포함하는 약학적 조성물 |
| AU2016377371A1 (en) | 2015-12-21 | 2018-08-09 | Bristol-Myers Squibb Company | Variant antibodies for site-specific conjugation |
| CN105717303A (zh) * | 2016-01-29 | 2016-06-29 | 山东康力医疗器械科技有限公司 | 一种用荧光免疫层析法检测磷酯酰肌醇蛋白聚糖3的方法及其试剂盒 |
| US11072666B2 (en) | 2016-03-14 | 2021-07-27 | Chugai Seiyaku Kabushiki Kaisha | Cell injury inducing therapeutic drug for use in cancer therapy |
| US20170326249A1 (en) | 2016-05-10 | 2017-11-16 | Bristol-Myers Squibb Company | Antibody-drug conjugate of an anti-glypican-3 antibody and a tubulysin analog, preparation and uses |
| US10994033B2 (en) | 2016-06-01 | 2021-05-04 | Bristol-Myers Squibb Company | Imaging methods using 18F-radiolabeled biologics |
| CN106084041A (zh) * | 2016-06-24 | 2016-11-09 | 安徽未名细胞治疗有限公司 | 一种全人源抗GPC3的全分子IgG抗体及其应用 |
| US20190262397A1 (en) | 2016-07-26 | 2019-08-29 | Tessa Therapeutics Pte. Ltd. | Chimeric antigen receptor |
| CN109641911B (zh) | 2016-08-19 | 2023-02-21 | 百时美施贵宝公司 | seco-环丙吡咯并吲哚化合物和其抗体-药物缀合物以及制备和使用方法 |
| US10398783B2 (en) | 2016-10-20 | 2019-09-03 | Bristol-Myers Squibb Company | Antiproliferative compounds and conjugates made therefrom |
| IL270138B2 (en) | 2017-04-26 | 2025-08-01 | Eureka Therapeutics Inc | Structures that specifically recognize glypican 3 and their uses |
| IL270596B2 (en) | 2017-05-25 | 2026-01-01 | Bristol Myers Squibb Co | Antibodies containing heavy constant regions are adapted for use in cancer therapy |
| CN109988240B (zh) * | 2017-12-29 | 2022-06-28 | 安源医药科技（上海）有限公司 | 抗gpc-3抗体及其用途 |
| CN112188902A (zh) | 2018-05-29 | 2021-01-05 | 百时美施贵宝公司 | 用于前药和缀合物的经修饰的自消灭部分以及使用和制造方法 |
| AU2019366956B2 (en) | 2018-10-23 | 2025-10-30 | Dragonfly Therapeutics, Inc. | Heterodimeric Fc-fused proteins |
| EP3887397A1 (en) | 2018-11-28 | 2021-10-06 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
| ES2943474T3 (es) | 2018-11-30 | 2023-06-13 | Bristol Myers Squibb Co | Anticuerpo que comprende una extensión carboxiterminal de una cadena ligera que contiene glutamina, conjugados del mismo, y métodos y usos |
| KR20210102334A (ko) | 2018-12-12 | 2021-08-19 | 브리스톨-마이어스 스큅 컴퍼니 | 트랜스글루타미나제 접합을 위해 변형된 항체, 그의 접합체, 및 방법 및 용도 |
| US12404341B2 (en) | 2019-03-21 | 2025-09-02 | Agency For Science, Technology And Research | Glypican-3 (GPC-3) antibodies |
| CN112390886B (zh) * | 2019-08-16 | 2022-08-16 | 原启生物科技(上海)有限责任公司 | 一种分离的抗原结合蛋白及其用途 |
| US20230272041A1 (en) | 2020-04-22 | 2023-08-31 | Dragonfly Therapeutics, Inc. | Formulation, Dosage Regimen, and Manufacturing Process for Heterodimeric FC-Fused Proteins |
| EP4146702A4 (en) * | 2020-05-07 | 2024-07-10 | Phanes Therapeutics, Inc. | Anti-tumor associated antigen antibodies and uses thereof |
| KR20230123495A (ko) | 2020-12-18 | 2023-08-23 | 아블린쓰 엔.브이. | 글리피칸-3 및 t세포 수용체를 표적으로 하는 면역글로불린단일 가변 도메인을 포함하는 폴리펩티드 |
| IL307927A (en) * | 2021-04-23 | 2023-12-01 | Shanghai Henlius Biotech Inc | Anti-gpc3 antibodies and methods of use |
| CN113354737B (zh) * | 2021-07-20 | 2022-11-18 | 广州爱思迈生物医药科技有限公司 | 一种磷脂酰肌醇蛋白聚糖3抗体及其应用 |
| IL310866A (en) * | 2021-08-19 | 2024-04-01 | Adicet Therapeutics Inc | Methods for the detection of membrane-bound glypican-3 |
| CN119080937A (zh) * | 2021-10-15 | 2024-12-06 | 乐普创一生物科技（上海）有限公司 | 抗磷脂酰肌醇蛋白聚糖3抗体 |
| JP2025535713A (ja) | 2022-10-07 | 2025-10-28 | アンブレツクス・インコーポレイテツド | 薬物リンカー及びその抗体コンジュゲート |
| KR20250096769A (ko) * | 2022-11-01 | 2025-06-27 | 상하이 치루 파마슈티컬 리서치 앤 디벨롭먼트 센터 리미티드 | 글리피칸-3에 대한 이중특이성 항체 및 이의 용도 |
| PE20260306A1 (es) | 2023-06-12 | 2026-02-11 | Amgen Inc | Proteinas de union a receptor de linfotoxina beta agonistas |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3426001B2 (ja) | 1993-09-16 | 2003-07-14 | 東芝機械株式会社 | ステージ内蔵型雰囲気室装置 |
| CA2219361C (en) * | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| CA2451493C (en) | 2001-06-22 | 2016-08-23 | Chugai Seiyaku Kabushiki Kaisha | Cell growth inhibitors containing anti-glypican 3 antibody |
| WO2004022597A1 (ja) * | 2002-09-04 | 2004-03-18 | Chugai Seiyaku Kabushiki Kaisha | Gpc3の血中可溶化ｎ端ﾍﾟﾌﾟﾁﾄﾞに対する抗体 |
| AU2002328429A1 (en) | 2002-09-04 | 2004-03-29 | Chugai Seiyaku Kabushiki Kaisha | CONSTRUCTION OF ANTIBODY USING MRL/lpr MOUSE |
| AU2002330482A1 (en) | 2002-09-04 | 2004-03-29 | Perseus Proteomics Inc. | Method of diagnosing cancer by detecting gpc3 |
| AU2003211292A1 (en) | 2003-01-30 | 2004-08-23 | Hongyang Wang | Monoclonal antibody against human hepatoma and use thereof |
| CN101562197B (zh) | 2003-06-27 | 2011-08-10 | 日本电气株式会社 | 薄膜晶体管、薄膜晶体管基板及电子设备 |
| CN1842540B (zh) | 2004-07-09 | 2012-07-04 | 中外制药株式会社 | 抗-磷脂酰肌醇蛋白聚糖3抗体 |
| KR20130103580A (ko) | 2004-08-24 | 2013-09-23 | 추가이 세이야쿠 가부시키가이샤 | 항 글리피칸 3 항체를 이용한 어쥬번트 요법 |
| CN101068836B (zh) | 2004-10-26 | 2013-08-14 | 中外制药株式会社 | 糖链改变的抗磷脂酰肌醇聚糖3抗体 |
| AU2005333155B2 (en) * | 2005-03-14 | 2011-11-17 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies against Hendra and Nipah viruses |
| CN104356236B (zh) * | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| US7744800B2 (en) | 2006-01-06 | 2010-06-29 | Molded Fiber Glass Companies | Method and apparatus for controlling the stacking height of stackable products during compression molding off stops |
| KR101552735B1 (ko) * | 2006-12-01 | 2015-09-14 | 메다렉스, 엘.엘.시. | 씨디22에 결합하는 인간 항체 및 이의 용도 |
| KR101570252B1 (ko) * | 2007-07-17 | 2015-11-19 | 메다렉스, 엘.엘.시. | 글리피칸-3에 대한 단클론 항체 |
| US8852599B2 (en) * | 2011-05-26 | 2014-10-07 | Bristol-Myers Squibb Company | Immunoconjugates, compositions for making them, and methods of making and use |
-
2008
- 2008-07-17 KR KR1020107003345A patent/KR101570252B1/ko not_active Expired - Fee Related
- 2008-07-17 RS RS20160157A patent/RS54624B1/sr unknown
- 2008-07-17 PL PL08796249T patent/PL2178921T3/pl unknown
- 2008-07-17 HU HUE08796249A patent/HUE028737T2/en unknown
- 2008-07-17 ME MEP-2016-86A patent/ME02345B/me unknown
- 2008-07-17 PT PT87962494T patent/PT2178921E/pt unknown
- 2008-07-17 ES ES08796249.4T patent/ES2562790T3/es active Active
- 2008-07-17 KR KR1020157007446A patent/KR101527342B1/ko not_active Expired - Fee Related
- 2008-07-17 SI SI200831584A patent/SI2178921T1/sl unknown
- 2008-07-17 AU AU2008275985A patent/AU2008275985B2/en not_active Ceased
- 2008-07-17 MX MX2010000537A patent/MX2010000537A/es active IP Right Grant
- 2008-07-17 HR HRP20160270TT patent/HRP20160270T1/hr unknown
- 2008-07-17 EP EP08796249.4A patent/EP2178921B1/en active Active
- 2008-07-17 WO PCT/US2008/070344 patent/WO2009012394A1/en not_active Ceased
- 2008-07-17 JP JP2010517161A patent/JP5868593B2/ja not_active Expired - Fee Related
- 2008-07-17 CN CN2008801031669A patent/CN101815726B/zh not_active Expired - Fee Related
- 2008-07-17 DK DK08796249.4T patent/DK2178921T3/en active
- 2008-07-17 US US12/668,965 patent/US8680247B2/en active Active
-
2014
- 2014-02-10 US US14/176,790 patent/US9217033B2/en active Active
- 2014-07-03 JP JP2014137921A patent/JP2014236734A/ja active Pending
-
2016
- 2016-03-01 CY CY20161100174T patent/CY1117236T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR101570252B1 (ko) | 2015-11-19 |
| HUE028737T2 (en) | 2017-01-30 |
| US20100209432A1 (en) | 2010-08-19 |
| WO2009012394A1 (en) | 2009-01-22 |
| US20140186892A1 (en) | 2014-07-03 |
| KR20150038732A (ko) | 2015-04-08 |
| ME02345B (me) | 2016-08-31 |
| SI2178921T1 (sl) | 2016-05-31 |
| ES2562790T3 (es) | 2016-03-08 |
| EP2178921B1 (en) | 2016-01-06 |
| CN101815726A (zh) | 2010-08-25 |
| KR20100056467A (ko) | 2010-05-27 |
| KR101527342B1 (ko) | 2015-06-09 |
| DK2178921T3 (en) | 2016-04-04 |
| JP5868593B2 (ja) | 2016-02-24 |
| EP2178921A1 (en) | 2010-04-28 |
| AU2008275985A1 (en) | 2009-01-22 |
| JP2010533498A (ja) | 2010-10-28 |
| HRP20160270T1 (hr) | 2016-05-06 |
| RS54624B1 (sr) | 2016-08-31 |
| CY1117236T1 (el) | 2017-04-05 |
| PT2178921E (pt) | 2016-03-23 |
| US9217033B2 (en) | 2015-12-22 |
| JP2014236734A (ja) | 2014-12-18 |
| CN101815726B (zh) | 2013-04-03 |
| AU2008275985B2 (en) | 2013-09-19 |
| US8680247B2 (en) | 2014-03-25 |
| MX2010000537A (es) | 2010-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2178921T3 (pl) | Monoklonalne przeciwciała przeciwko glipikanowi-3 | |
| IL200168A0 (en) | Monoclonal anti-cxcl13 antibodies | |
| EP2331579A4 (en) | MONOCLONAL ANTIBODIES | |
| HRP20181616T1 (hr) | Potpuno ljudska anti-vap-1 monoklonska antitijela | |
| SG10201601279SA (en) | Monoclonal Antibody STRO-4 | |
| ZA201000049B (en) | Monoclonal antibeta amyloid antibody | |
| GB0708002D0 (en) | Antibodies | |
| IL204835A0 (en) | Humanized antibody | |
| IL201983A (en) | Antibody against pan nrpa | |
| SI2146745T1 (sl) | Penta-specifično protitelo | |
| ZA201002422B (en) | Modified antibody constant region | |
| SI2200700T1 (sl) | Nova protitelesa | |
| EP2138576A4 (en) | ANTI-CLAUDIN-4 ANTIBODY | |
| GB0720912D0 (en) | Monoclonal Anitbody for APP | |
| ZA201202227B (en) | Monoclonal antibodies | |
| GB0718737D0 (en) | Antibodies | |
| EP2198055A4 (en) | HUMANIZED PAI-1 ANTIBODIES | |
| IL205073A0 (en) | Anti-bst2 antibody | |
| GB0702888D0 (en) | Novel Antibodies | |
| IL199974A0 (en) | Humanized antibodies against cxcr3 | |
| ZA200901481B (en) | Smallpox monoclonal antibody | |
| GB0706965D0 (en) | Humanized antibody | |
| GB0706964D0 (en) | Humanized antibody | |
| GB0706963D0 (en) | Humanized antibody | |
| AU2008903401A0 (en) | Anti-C5L2 monoclonal antibodies |